SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Boehringer Ingelheim Pharmaceuticals, Inc. Completes Enrollment of Pivotal Phase III Studies for Nintedanib (BIBF 1120) in Idiopathic Pulmonary Fibrosis